Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Accumulated Expenses (2023 - 2025)

Bioregenx has reported Accumulated Expenses over the past 3 years, most recently at $434370.0 for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 2.38% year-over-year to $434370.0; the TTM value through Dec 2025 reached $434370.0, up 2.38%, while the annual FY2025 figure was $434370.0, 2.38% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $434370.0 at Bioregenx, up from $380599.0 in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $459732.0 in Q1 2025 and troughed at $321897.0 in Q1 2024.
  • A 3-year average of $395001.2 and a median of $398058.0 in 2024 define the central range for Accumulated Expenses.
  • On a YoY basis, Accumulated Expenses climbed as much as 42.82% in 2025 and fell as far as 0.86% in 2025.
  • Year by year, Accumulated Expenses stood at $346677.0 in 2023, then grew by 22.38% to $424277.0 in 2024, then rose by 2.38% to $434370.0 in 2025.
  • Business Quant data shows Accumulated Expenses for BRGX at $434370.0 in Q4 2025, $380599.0 in Q3 2025, and $405495.0 in Q2 2025.